Zimbabwe has rejected a substantial US health deal valued at 367 million US dollars (272 million pounds) over five years because of the United States' demand for sensitive data.
This rejection was revealed after a official document from December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "unbalanced".
An official spokesman later clarified that the US was demanding access to genetic material for scientific study and commercial purposes but was unwilling to guarantee the resulting advantages from any future medical innovations.
"We are forced to start the difficult and regrettable process of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had provided more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged more negotiations to find a deal suitable to both sides so the country's vital HIV programme can proceed.
Broader Implications
This development follows a comparable case in Kenya, where a high court blocked a similar health funding agreement following concerns were filed about the safety of citizens' medical information.
After returning to office last year, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump stated its expenditure was "inefficient" and his administration was seeking government-to-government deals to enhance transparency and responsibility.
Based on reports, Sixteen African countries have to date agreed to these new agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Deal
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment via American-funded initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to provide its genetic material and health information for a long time, without any equivalent promise of benefiting from any scientific breakthroughs – like new medicines or tests – that might be developed from that provided information," Mangwana explained.
"In essence, our country would supply the basic resources for scientific discovery with no certainty that the resulting innovations would be available to our people should a future pandemic emerge."
National Interest and International Frameworks
He also said that the American exit from the global health body and its push of one-on-one deals were upending systems already set up via the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing framework designed to deal with future pandemics.
"This mechanism is intended to ensure that when a country provides its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to develop them."
The government's concerns over the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome continued dialogue with our American counterparts on how future co-operation might be arranged in a way that respects the sovereignty and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but urged that talks should continue considering a large portion of the country's HIV programmes relied on external financing.
"Where technical issues arise, such as those relating to data governance or implementation frameworks, these can frequently be resolved via technical clarification and negotiated safeguards," it said.
The situation highlights the ongoing tensions between accepting vital international aid and safeguarding a country's data in an increasingly data-driven world.